We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Andrew
Pollard
andrew.pollard@paediatrics.ox.ac.uk
Mr
Richard
Sewell
richard.sewell@paediatrics.ox.ac.uk
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Sorry, this information is not available
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Vaccine;
You can take part if:
You may not be able to take part if:
The potential participants may NOT enter the study if ANY of teh following apply: - Participant(s) in original study (NCT00980850)(1) who had a suspected unexpected serious adverse reaction (SUSAR) -History of severe allergic reaction after prrevious vaccinations or hypersensitivity to any seasonal influenza vaccine component -Current egg allergy - Known or suspected impairment/alteration of teh immune system - Disorders of coagulation - Immunosuppressive therapy, use of systematic corticosteroids for more than 1 week within the 3 months prior to enrolment - Receipt of blood, blood products and/or plasma derivatives or any immunoglobulin preparation within the 3 months prior to enrolment - Previous receipt of, or intent to imunize with, any other seasonal influenza vaccine(s) throughout the 2010/2011 influenza season - Participationin another clinical trial of an investigation medical product - Any condition which, in th opinion of the investoigator, might interfere with the evalution of the study objective. Children with chronic, stable medical illnesses that do not result in immunosuppression (e.g. cerebral palsy, epilepsy, cystic fibrosis, congenital heart disease) will be allowed to participate in the study, unless these conditions will in some way interfere with teh completion of the study procedures. Children with conditions that alter the immune response to vaccines (e.g. Trisomy 21) or will affect the ability to accurately describe adverse events (e.g. children over 5 years of age but with severe learning difficulties) will be excluded.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mr
Richard
Sewell
richard.sewell@paediatrics.ox.ac.uk
Prof
Andrew
Pollard
andrew.pollard@paediatrics.ox.ac.uk
The study is sponsored by University of Oxford and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 9422
You can print or share the study information with your GP/healthcare provider or contact the research team directly.